Loading…
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd (RDY) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Hyderabad, India and has 27,527 employees. The company is worth $11.02B and trades at 30.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was ₹335.93B in fiscal 2026, up 3.2% from the year before. Net income was ₹42.85B. The share price is 15.6% below its 52-week high of $15.67. It pays a dividend yielding 0.60%. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $106.46M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in INR, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +4.7% over 5Y.
today you would have $1,116.47▲ +11.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $13.07 | $14.04 | $15.79 | $13.92 | |
| EPS | ₹51.42 | ₹67.78 | ₹66.92 | ₹54.17 | |
| Dividend yield | 0.64% | 0.64% | 0.65% | 0.61% | 1.40% |
| Profit margin | 17.85% | 12.76% | 17.37% | 19.95% | 18.33% |
| ROE | 18.24% | 11.36% | 16.96% |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALGNAlign Technology Inc | $155.51 | 26.3x | 2.6x | 0.00% | 10.15% | $11.05B |
| GMEDGlobus Medical Inc | $81.66 | 20.2x | 2.3x | 0.00% | 11.81% | $10.96B |
| BMRNBiomarin Pharmaceutical Inc | $56.63 | 153.1x | 1.7x | 0.00% | 1.18% | $10.96B |
| UHSUniversal Health Services Inc |
| 19.85% |
| 19.51% |
This company reports in INR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by INR, so they are not shown; EPS is in INR. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
2 methods answered, across 1 families.
Room for errors in the reported numbers.
-48.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $188.13 |
| 7.7x |
| 1.5x |
| 0.43% |
| 20.95% |
| $11.09B |
| MOHMolina Healthcare Inc | $216.64 | — | 2.7x | 0.00% | -0.16% | $11.31B |
| ELANElanco Animal Health Inc | $22.69 | — | 1.7x | 0.00% | -2.98% | $11.33B |